Trying a new protein substitute for PKU
Part of Brain & nervous system, Genetic & congenital, Hormones & metabolism clinical trials.
This trial is testing a new slow-release protein substitute for people with PKU, to see if it is acceptable and well-tolerated. You would try the product for 7 days, replacing your usual substitute, to see how it fits into your routine.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with PKU or high phenylalanine levels that need a special protein substitute.
- You are already taking a phenylalanine-free protein substitute and are willing to try a new one for 7 days.
- You are at least 3 years old.
- You are not currently taking antibiotics, and haven't taken any in the past 2 weeks.
- You are not participating in any other research study right now or within the last 2 weeks.
- You do not have any serious illness that might interfere with the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a specific mix of large neutral amino acids (LNAAs) can help adults with classical PKU by lowering phenylalanine levels in the brain. It includes an MRI and PET scan to see how the treatment affects brain activity.
This study is testing whether a new microtablet form of protein substitute is easy and acceptable for people with PKU to take. If you qualify, you'll take these tablets instead of your current protein substitute and share your experience with the research team.
This trial tests a new powdered protein substitute (GMP) for people with PKU or tyrosinemia. It aims to see if it is a safe and effective option to help manage their condition.
This trial tests an experimental medication taken as a pill to see if it can help people with PKU manage their condition. The study will check if the pill is safe and how it affects blood phenylalanine levels.
This trial tests an investigational drug (AG-181) for people with PKU who have a specific genetic change (R408W mutation). It aims to check if the drug is safe and how it works in your body.
This study tests a new injection called PL54 to see if it is safe and tolerable for adults with phenylketonuria (PKU), a condition where the body cannot break down an amino acid called phenylalanine. It is designed for people with high blood phenylalanine levels and may offer a new treatment option.
Hear when a new Brain Diseases, Metabolic, Inborn trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.